DaVita Inc. (DVA) Earnings Call Transcript & Summary

November 7, 2023

New York Stock Exchange US Health Care Health Care Providers and Services earnings 61 min

Earnings Call Speaker Segments

Nic Eliason

executive
#1

Thanks for joining us for the Q3 conference call, and we're glad you continue to take an interest in the company. This is Nic Eliason, Group Vice President of Investor Relations. With me today are our CEO, Javier Rodriguez, our CFO, Joel Ackerman, and Dr. Jeffrey Giullian, our Chief Medical Officer. I'd like to point out that on this call we'll be making forward-looking statements as that term is defined under the federal securities laws. Known and unknown risks and uncertainties apply to every one of these statements, and those risks and uncertainties could make actual results vary materially from what the forward-looking statements describe. If you want more information about those risks and uncertainties, take a look at our Q3 earnings press release and our SEC filings — that includes our latest annual report on Form 10-K, every quarterly report on Form 10-Q filed afterward, and any other subsequent filings we make with the SEC. The information we currently have available forms the basis for our forward-looking statements, and we neither intend nor assume any obligation to update them, except where the law requires it. We'd also like to remind everyone that certain Non-GAAP financial measures will be discussed on this call. You can find a reconciliation of those Non-GAAP measures to the most comparable GAAP financial measures in our earnings press release, which has been furnished to the SEC and is available on our website. At this point, I'll hand the call over to Javier Rodriguez.

Javier Rodriguez

executive
#2

I appreciate the chance to speak, Nic, and I'm grateful to everyone following DaVita. Another robust quarter is behind us. Early in the year, we moved faster than anticipated on numerous core operational goals, and that forward motion carried over into Q3. We've kept a sharp eye on short-term operational rigor while still putting money into growth down the road. Meanwhile, we're building a distinctive experience for our team members and, naturally, providing the best possible care to those we treat. Today I'll cover how we performed in Q3, offer our view on what GLP-1 medications could mean for us, give an update on 2023 guidance, and finish with a few reflections about the coming year. Before diving into Q3 specifics, I want to open, as is my habit, with a clinical achievement. This time, the spotlight falls on our operations abroad, where we look after over 40,000 patients in 11 countries. Every nation differs when it comes to health conditions, how medicine is practiced locally, and oversight rules. Across the last 5 years, we built universal protocols that marry our kidney care know-how with each country's local approaches. Since we rolled out this proprietary framework, clinical outcomes have improved consistently and substantially. We now beat the clinical benchmarks in each international market where we have a presence, and taken together, all-cause patient mortality throughout our international countries has fallen 20% since 2020. Results of this kind touch the very heart of who we are as an organization — one whose purpose is to add years to patients' lives and improve how well they live. Now for the financial picture: the third quarter came in strong, delivering adjusted operating income of $525 million alongside adjusted earnings per share of $2.85. Both figures came in above our earlier guidance for the quarter. Our core operating measures continued to hold up nicely, and we additionally benefited from favorable seasonality and timing effects. I'd like to walk through three specific areas now: patient census, the costs associated with patient care, and integrated kidney care, which we refer to as IKC. First off, following the increase we saw during the opening six months of the year, the number of patients we serve has remained steady, and we expect to finish the year with 1,500 to 2,000 more patients than we had when 2022 came to a close. In 2023, mortality continues to decline, which is in line with what we projected. Should those trends continue, we expect volume growth to turn positive again in 2024 and beyond. Next, our costs for patient care continued to fall throughout Q3. Beyond typical seasonal patterns, a large portion of that decrease came from our move to Mircera for managing anemia. That said, wage increases remain higher than they have historically been and are rising faster than revenue per treatment, even though they landed below our forecast for the quarter. What we're seeing on labor aligns with recent macroeconomic patterns. A tight labor market and low unemployment keep pressuring retention and training, partly offset by a modest softening in wages. And wrapping up, our IKC segment delivered a robust quarter and is running ahead of what we projected for the full year. We're driving better health results for patients while bringing down the overall expense of care, and that produces savings split between DaVita and our partners. On top of that, we recognized revenue tied to those savings sooner in the year than we had expected. We keep putting money into growth even as we tightly control the costs of our care model, and our multi-year roadmap toward reaching breakeven by 2026 remains on schedule. Moving to something that's drawn attention lately. Much has been said about GLP-1 drugs, with plenty of speculation about how they might affect dialysis growth rates. The evidence that these medications could boost the health of many people around the world is something we find exciting. That said, as more data comes in suggesting these medications could help with obesity, diabetes, and heart conditions, we haven't changed our position: the impact on dialysis volumes ought to be limited. We'd maintain that stance even if upcoming trial data shows a benefit for slowing chronic kidney disease, or CKD. To explain how we see it, breaking the population down by disease stage is important. For people who haven't yet reached CKD Stage 3, it makes sense that reducing obesity would lead to fewer diabetes and hypertension diagnoses, fewer chronic kidney disease cases, and ultimately fewer dialysis patients. That thesis rests on numerous unknowns within a progressive disease, yet timing is the one place where clarity is possible. Within this group, reaching end-stage renal disease usually takes 15 to 20 years or more. Needless to say, such a scenario sits past the horizon of our strategic plan; now, shifting to the late-stage CKD population, four key factors strike us as important. First, the rate of GLP-1 adoption among the CKD population. Second, how CKD progression is affected. Third, the offsetting effect from the cardiac mortality benefit. Finally, what happens to payer mix because of any shift in the average patient age. To build a conservative forecast, we presume strong adoption and long-term adherence, partly supported by the chance of heavy uptake among people who might use GLP-1s for obesity rather than for CKD benefits. We likewise examined a broad spectrum of potential clinical effects from trials both current and future. Running simulations across those assumptions, the midpoint of our model shows a neutral effect on 10-year dialysis growth rates, alongside a small but immaterial effect on payer mix. We know this might not seem intuitive, which is exactly why several poorly understood traits of kidney disease must be taken into account. Consider the roughly 16 million people in the U.S. today at CKD Stage 3 and beyond: across the coming 10 years, approximately 75% will die before ever reaching end-stage kidney disease. That figure stands against fewer than 10% of those individuals who will eventually move on to dialysis. Since cardiovascular complications are the primary contributor to deaths in this group, the advantage gained by preventing more of those events can benefit a much larger population than any benefit related to delaying disease progression. To get a clearer picture of the potential worst case for dialysis growth, we ran another model assuming that both FLOW and SELECT demonstrate efficacy on every kidney endpoint, while cardiac mortality provides no offsetting gain whatsoever. Let me be clear: we do not anticipate this outcome. According to our modeling, it would create a 0.5% yearly drag on growth across that same decade, translating to roughly $25 million in annual operating income headwind. To close, I want to address the gap between how we see things and what we think the market believes. Let me be clear: that gap has nothing to do with how popular GLP-1 drugs are or the many health advantages they offer. It's specifically about the effect on kidney care. So we brought in outside epidemiologists and consultants to stress-test our analytics, reviewing the existing research extensively and testing a broad range of assumptions. We avoided focusing on the middle of the range. Instead, we adopted the pessimistic scenario for volume and factored in possible financial challenges that could arise from a lower commercial mix. Ultimately, what we've concluded, given what we know at this point, is that even with strong uptake of these drugs, we'll still hit our long-term targets for operating income growth over the coming 10 years. This subject is complex, and we're glad to go deeper or take any questions about our assumptions. Moving to another matter. As we look ahead to Q4, we're changing our 2023 adjusted operating income guidance range from $1.565 billion-$1.675 billion to a new range of $1.65 billion-$1.725 billion. We are raising our adjusted EPS outlook as well. Previously it stood at $7 to $7.80 per share, and now we're putting it at $7.80 to $8.30 per share. As for next year, guidance would be premature at this point, though volume and adjusted operating income should both grow in 2024. Cost pressures are still with us, and we remain dedicated to putting money into our team members, yet we still anticipate that the middle of our 2024 adjusted operating income guidance will land inside the 3%-7% long-term target growth rate, thanks to ongoing gains from our operating initiatives. More specifics will come during our Q4 call. I'll hand things over to Joel now so he can walk through our financial performance and outlook in greater detail.

Joel Ackerman

executive
#3

Thanks, Javier. I'll walk through the strong numbers we posted this quarter, give you my take on what to expect in Q4, and bring you up to speed on how we're putting capital to work... Starting with volume: Q3 played out just as we thought it would. Our daily U.S. dialysis treatments and patient census were basically flat versus Q2, and admits grew year over year for a third straight quarter — something we hadn't seen since COVID-19 first hit. The 12-month rolling mortality rate continues to decline. With another quarter-over-quarter gain, we're now close to where mortality stood before the pandemic. Compared with Q2, revenue per treatment was up $3.60. That improvement reflects continued gains in revenue cycle performance, the usual contractual rate bumps, and a larger share of private pay. Looking at the full year, we expect to finish close to the upper boundary of that 2.5%-3% year-over-year RPT guidance we gave you during our prior quarterly call. Now shifting to 2024: the final Medicare PPS rate for ESRD was published last week. CMS did recognize that its 2022 forecast error came in larger than first estimated, yet the net rate update that got finalized for 2024 amounted to only 2.1%. Given ongoing forecasting misses, today's inflation, and other rising expenses, that figure still sits below what we view as suitable. With that said, even while RPT growth lags the inflation we're currently seeing, we continue to uncover opportunities to expand margin. Sequentially, our non-GAAP patient care cost per treatment dropped by $2.30. Like Javier mentioned, a few different things drove this, including the changeover to Mircera for treating anemia. Within IKC, we saw a $50 million gain from one quarter to the next, and that came from two sources. The first is that shared savings revenue we booked in Q3 came in at about $45 million above the Q2 figure. Worth pointing out — that's better than what we had projected, though it's largely a matter of timing, because we'd been counting on that money arriving in Q4. The second is that during the quarter we picked up $15 million in favorable adjustments tied to reconciliations for our Special Needs Plans. Those gains were partly eaten up by roughly $10 million in added costs. Because so much of the shared savings revenue landed in Q3, we expect IKC's operating results to come in lower in Q4 than they were in Q3. As we've noted previously, this business tends to swing somewhat from quarter to quarter, so looking at the full year gives a clearer picture of how we're doing. We're still seeing progress in IKC, and our expectation for the entire 2023 year is now an adjusted operating loss of roughly $110 million for that segment, a bit better than what we guided to earlier for 2023. On Q4 specifically, the operating income guidance we've updated points to adjusted operating income of $380 million, which works out to a drop of about $145 million from one quarter to the next. Most of that gap comes from a pair of things — IKC and seasonality. With IKC, the fourth quarter will come in lower, mainly because of timing, which we already flagged. As we look toward Q4, normal seasonal patterns should apply, driven by several items: missed treatments usually climb over the holidays, our spending on team member health benefits increases, G&A rises, and additional year-end costs hit in Q4. The seasonal movement this year is larger than a typical Q4. We closed or combined 15 clinics in Q3, taking our year-to-date figure to 51. We'll continue to evaluate our footprint against utilization trends. Turning to taxes, our full year 2023 tax rate is now projected at roughly 23%-24%, a drop from the range we gave previously for the year. The revised range reflects bigger benefits tied to stock-based compensation along with anticipated tax credits. Moving over to the balance sheet, our approach to capital allocation is still centered on growth that's efficient with capital. As we've noted before, our long-term objective is a leverage ratio between 3 and 3.5 times EBITDA, and a year ago we halted our share repurchase program as part of the effort to get back into that range. So we bought back no shares during the quarter just ended, and we finished that quarter with a leverage ratio sitting near the midpoint of our target range. Given that, and after weighing our standard capital allocation principles — among them how we see intrinsic value against where our stock currently trades — we plan to restart share buybacks this quarter. We anticipate funding those repurchases through a mix of excess cash flow and available room under our revolving credit facility. As a reminder, we increased the size of our revolver earlier in the year, giving us greater liquidity and flexibility in our capital structure. We keep managing our exposure to climbing interest rates. About 50% of what we owe sits in long-dated notes with really attractive locked-in rates, and the other 50% moves with the market. We've got caps lined up through the close of 2025 that take care of the bulk of that risk; that's everything I had ready to say. Operator? ... Let's take questions from the line.

Pito Chickering

analyst
#4

Hello, good afternoon, and thanks for making time for my questions. I have a few things I want to ask about. On patient care costs versus a year ago, you saw fairly significant declines both year over year and sequentially. You brought up adjustments and efforts to keep things managed. Can you take us through what drove those movements and help us connect the dots? And even though you're not talking about 2024, you've clearly done a strong job holding expenses in check this year. Do you think that same kind of opportunity will be available as we head into next year?

Joel Ackerman

executive
#5

Yeah, I appreciate that, Pito. On the patient care cost side, the best way to think about it is that wage rate pressure remains, and we are certainly seeing that. When you look at SWBs, the decline in contract labor offsets it. Remember, 12 months ago that was a big problem for us, and we got it under control pretty early. So what you're probably seeing is roughly $100 million, maybe a little less than that, but in that neighborhood of savings versus a year ago. On other items, we've done a good job managing our anemia costs. We've talked about that with the reduction from the shift to Mircera, and beyond that, there are additional savings from us reducing our footprint since patient volumes have fallen. Those are the primary drivers versus last year. Turning to 2024, I think we expect to continue seeing wage rate pressure relative to a pre-COVID number. I don't think we're ready to give guidance on where that lands, but it certainly won't go back to the pre-COVID level based on what we see right now. We would expect some continued savings as the benefits from both Mircera and our facility closures are fully realized across the year. After that, as you can imagine, we'll keep looking for other ways to reduce costs, to offset what will ultimately be greater wage rate pressure than what we experience in our RPT growth, and that's likely in the range of $3 million to $3.5 million.

Pito Chickering

analyst
#6

All right. Then let's turn to the GLP-1s. You know, we attempted something similar a few weeks back, trying to build out a model spanning 10 years. There are certainly plenty of moving pieces involved. Is there any possibility you'd be willing to share the model you had, so we can experiment with the assumptions, you know, among those variables? And, you know, at the same time, could you tell us about what you observed with SGLT2 inhibitors? Yeah, what kind of impact did you see from CKD patients, you know, progressing into end-stage renal disease because of that drug, and just, you know, when you consider the impact from GLP-1s?

Javier Rodriguez

executive
#7

Well, Pito, it's Javier here, and I read your notes, so you've been immersed in all this complexity. So, given that familiarity and understanding vary among people on the call, and as you know, these variables interact with each other, I think it would be worthwhile to take a step back and establish a common foundation so all of us can, start from the same point; so to arrive at that model you requested, what I'm going to ask is, first for our chief medical officer, Dr. Giullian, to give a high-level overview of the clinical side, and then, I'll pass it to Joel, and he can provide us with some of the financial impact, so we could offer you a framework, and after that we can discuss assumptions. Is that fair?

Pito Chickering

analyst
#8

Sounds good.

Javier Rodriguez

executive
#9

All right, Dr. G.

Jeffrey Giullian

executive
#10

Okay, that's great. Thank you, Pito. I want to begin by acknowledging the excitement that currently exists in society surrounding these treatments. As Javier said at the start, I feel encouraged—and I believe all of us do—that these products have the potential to genuinely transform many individuals' lives. We absolutely support using therapies that help patients suffering from heart disease as well as those dealing with kidney disease. Regarding GLP-1 agonists, they have been on the market since 2005. These agents have produced numerous rigorous clinical trials. What struck me as interesting is that under half of the research that examined kidney disease at all showed any effectiveness when it came to slowing progression. Specifically, roughly 40% of those trials revealed no benefit, another 40% indicated improvement in certain respects, and around 20% yielded results that were somewhat mixed. Then, naturally, among those showing that benefit or effect, the largest effect appeared within a particular patient subgroup—and that is essentially where our whole approach began. Now, you might be asking yourself—I believe the two most common questions I receive are: first, what proportion of individuals will eventually, or do we anticipate will eventually, be taking these drugs? And second, what percentage reduction in CKD progression will that produce? So allow me to take you through our clinical reasoning, and afterward I'll pass it to Joel, who can discuss the financial side further. On that initial question: roughly 5%-8% of CKD patients currently receive these drugs, and published rates of discontinuation reach as high as 69%. To stay quite conservative in our modeling, we eventually projected that roughly 30% of CKD patients might one day be on these therapies. We reached that figure by triangulating across multiple data sources. We examined adoption patterns for other drugs, including generics, that are recognized for slowing kidney deterioration. We examined clinical eligibility among patients... On that specific point, approximately 70% of CKD patients who eventually reach dialysis are either obese, diabetic, or both, while the remaining 30% are essentially not candidates for these medications. We assumed roughly 40% of those who qualify might receive these therapies down the road, which would amount to, at most, we believe, about 30% of the overall CKD population being on these medicines among those who ultimately progress to dialysis. That covers the first part. The second part concerns how to gauge the impact. We approached that by examining what we understand about assessing the slowing of disease progression—namely, whether any delay occurs with these medicines. At present, we estimate a 25% delay in progression. To get to that figure, we examined the effect within the subset of clinical trials that did show efficacy for renal progression. And like I said, roughly 40% of those studies fit that. After that, we took the data points from the smaller subpopulations within those studies in which the medications showed benefit. And overall, that came out to around 25%, and we relied on that 25% to extrapolate across the broader CKD population. And again, the intent there was to stay conservative in how we approached it; and I'll just wrap up by noting that no therapy has truly been shown to stop progression or reverse kidney damage over time. So that speaks to the second half of your question, which covers the SGLT2s. At present, roughly 8% of our ESRD population has received an SGLT2, and that reflects several factors, among them the fact that around 65% of patients who are prescribed those medications end up discontinuing them; so that effect, we believe, is something we've already accounted for in our model, and I'll let Joel add a bit more on that.

Joel Ackerman

executive
#11

Alright, thank you, Dr. Giullian. I've been fortunate to spend many weeks deeply immersed in the clinical side of this alongside Dr. Giullian, other kidney specialists, and epidemiologists — those both within and outside our organization. So allow me to recap the points Dr. Giullian made, and after that I'll get into our modeling. There are three things I'd highlight. To begin with, we didn't just make up our assumptions. These GLP-1 medications have been prescribed for diabetes management for a minimum of 7 or 8 years, so as Jeff mentioned, there are numerous solid studies — meaning there's a dataset available to base certain assumptions on. That being said, considerable uncertainty remains, and our aim was to stay conservative. So we settled on 2 assumptions that feed into our modeling. The first: 30% of the CKD population will be taking these drugs. This won't occur all at once; it will unfold gradually. That's part of what makes the modeling so complicated. So that's assumption one — a 30% utilization rate, or penetration rate, within our population. Once again, we believe that figure is conservative. The second: a 25% efficacy rate, which means that for patients on this drug, their CKD progression gets slowed by 25%. To make that concrete, imagine a typical CKD patient moving from a later stage of CKD to ESRD across 10 years — that would stretch the 10-year progression out to 12.5 years. Those are the clinical inputs feeding our modeling. Now let me shift to how we modeled two separate numbers. The first one I'll address is commercial mix impact. I'll begin here since I think it's somewhat simpler to grasp, and the financial consequences could be significant — but what you'll find is that they aren't, and here's the reason. As you'd expect, we have a very strong model for this, which we've relied on to simulate the impact across numerous scenarios. We also use it to build a greatly simplified framework for explaining how we're approaching this, so let me begin that framework with a few known inputs. First, roughly 22,000 commercial patients is what we have right now — that much we know. Second, once again, the majority of our patients aged 65 and above aren't commercially insured. For modeling purposes, it's reasonable to assume the over-65 population has a commercial mix of essentially zero. And regarding the commercial mix of our incident patients under 65, it stays fairly steady. Whether they're 40, 50, or 60 doesn't matter — it's a fairly steady figure, and that figure declines once they reach 65. What that curve shape means is this: if we try to model how a delay in progression caused by GLP-1 affects commercial mix, the only group that truly matters is patients just under age 65 who, absent GLP-1, would have become incident to dialysis with commercial insurance … yet thanks to GLP-1s, that incidence gets pushed back, so rather than becoming incident below 65, they become incident above 65. With that framework in place, allow me to lay out our assumptions. To start, we're discussing a 25% delay in progression. We've already addressed that. As I mentioned, this converts into a 2.5-year window of incident patients that concern us. And here's a key point: roughly 10% of our commercial population becomes incident during that 2.5-year window prior to 65. Put differently, 10% of our commercial population falls between age 62.5 and 64; so the math works like this. Take 22,000 patients, presume 10% of them sit in that incident window of 62.5 to 64 that concerns us, and assume 30% of them will be taking the GLP-1 drug, which gives you 22,000 × 10% × 30%; that equals 660 patients. That figure represents the commercial patients we'd anticipate losing from GLP-1 penetration reaching 30%; those 660 patients, divided by our 200,000 patients, comes to 33 basis points of commercial mix. So let me restate plainly what those 33 basis points of commercial mix represent. They represent the cumulative effect of GLP-1 growth, no matter how long it takes us to reach that 30% and watch it flow through our CKD population, amounting to a reduction of 33 basis points overall. Should that occur across 10 years, it works out to roughly 3 basis points annually. That is a negligible amount. For context, our commercial mix rose 18 basis points this quarter by itself. You would never spot this in our numbers. That's why we hold the view that commercial mix effectively won't shift because of a delay in progression.

Javier Rodriguez

executive
#12

Okay, Pito, we made quite a lengthy statement only to lay the groundwork. Naturally, there's a second component, and that's simply total volume, but our intention was to begin with commercial patients and what's happening there, which, as Joel mentioned, carries no real financial significance. So, does anyone have anything to ask about that?

Pito Chickering

analyst
#13

All right, I'll need to take everything you said and apply it back to the models, but that answer was extremely thorough. I'll get back in line for additional questions shortly. Thanks very much.

Justin Lake

analyst
#14

Thank you. I appreciate the level of detail. That was amazing; let me pick up on one item you mentioned, the 30%. In a CKD population that is aware it is heading toward dial — toward ESRD and dialysis — that 30% figure exists. What's the reasoning underlying it? I would have assumed it could be greater, considering the eventual outcome of kidney failure.

Jeffrey Giullian

executive
#15

Yes, thank you, Justin. Speaking is Jeffrey Giullian. We have examined quite a few factors. For 20 years or more, we are aware that generic drugs — ACE inhibitors and ARBs — have been available on the market with a solid effect on possibly decelerating the advancement of renal disease. If you examine how many patients take those drugs, including the ones you just mentioned who are aware they are moving through CKD, that rate falls somewhere from just 17.8% to roughly 30%-35% of the population; and those drugs usually have a somewhat reduced discontinuation rate compared with the GLP-1. So with that in mind, we have a fairly solid benchmark for what uptake of these drugs should look like.

Javier Rodriguez

executive
#16

Also, Justin, keep in mind that 40% is the more useful way to look at it, since 30% fall into neither the diabetic nor the obese category, so while it comes to 30% across the board, among those the figure applies to, it's 40%. And we were—

Justin Lake

analyst
#17

Understood. Understood.

Javier Rodriguez

executive
#18

And the assumption we're working with is full adherence at 100%, which isn't the usual way we'd model it. Our aim is simply to stay as cautious as possible, since, as Dr. G pointed out, a great many individuals stop taking the medication. In fact, a figure worth noting is that beyond 50% do so following the first year.

Justin Lake

analyst
#19

Doc, please walk us through again the reason that number stays so low for people whose kidney disease is getting worse? Why is the uptake rate only 18%-30%? With some of the trials coming out now showing the benefits, wouldn't you expect that to rise — or were those benefits, and how big they are, already well understood, and there are reasons it remains at that level?

Jeffrey Giullian

executive
#20

Yeah, to grasp why patients choose what they do or don't do takes a lot of guessing. Part of it has to do with whether individuals can get to doctors and drugs, along with social determinants of health. Another part has to do with how often people discontinue therapy, for many reasons, such as side effects and things like that. And frankly, our clinical research group has looked at the population of patients who ultimately go from CKD to end-stage renal disease. There are just many social and other elements, including behavioral health, education, and so on, that keep it from becoming the full 3% to 3.5% adoption one would predict on paper.

Justin Lake

analyst
#21

Understood. Thanks for that. Then I have a couple of fast numerical questions, and I'll get out of the way. First off, could you share what your run rate looks like for patient care expenses that are presently driven by drugs? I'm merely attempting to grasp the full picture of where drug spending stands right now. Second, Joel, looking backward, it's great to learn that you're sort of going to resume repurchasing the stock. As I recall, the most recent occasion you were purchasing it, back in 2022, I believe you averaged approximately $200 million each quarter. Might investors regard that as a sensible sort of starting point regarding how to think about your sort of buyback pace? Thank you.

Joel Ackerman

executive
#22

Yes, I'll address the buyback item first. Regarding pace, putting a figure out there is difficult. I'd say, look, we've consistently felt at ease employing surplus cash flow plus accessible leverage to repurchase. What I'd highlight is that our revolver is larger than it has been in the past; historically we had a billion-dollar revolver. We increased it to $1.5 billion. So considering the constraint of liquidity on our share repurchases, we'd likely feel more at ease drawing on the revolver for buybacks at this point, given that we now have a larger revolver than previously.

Javier Rodriguez

executive
#23

The second thing you asked about is the cost for each treatment, or what percentage that comes to.

Joel Ackerman

executive
#24

Drugs.

Javier Rodriguez

executive
#25

-on drugs?

Joel Ackerman

executive
#26

Right, absolutely. I’d say your focus is probably on anemia—that’s where we’ve seen the largest cost reductions. That figure has dropped significantly, to the point that, in my view, it’s tough to count on much further substantial savings from it moving ahead.

Justin Lake

analyst
#27

That's helpful. Thanks, guys.

Javier Rodriguez

executive
#28

Thank you, Justin.

Kevin Fischbeck

analyst
#29

Great, thanks. Perhaps just to return to what was said about the buyback. Can we safely say the 3 to 3.5 remains the determining condition for it, then? Or, since you now feel better about your base EBITDA and the capacity to grow, would you be fine, over some stretch of time, with going past 3.5, knowing you'd return to that 3 to 3.5?

Javier Rodriguez

executive
#30

Yeah, Kevin, I wouldn't look at it as something that rules it out, but instead, sort of, we made a commitment to get back to that spot, and now we're at it, and we're at ease being there, and we'll move back and forth however we deem suitable. At present, we perceive a gap between the way we feel regarding our business and the way the market is reading our results; and so we could act quite aggressively, and so that's, naturally, a term of art, because if I employ it and I purchase $300 million, you're going to believe it was $400 million. And so, I've always stated, from where I sit, the proper way to consider it is, we want to hand our money back to our shareholders, and we want to be capital efficient, and we want to pounce if an opportunity or a window appears. And that's probably the best way to consider it.

Kevin Fischbeck

analyst
#31

Kevin, glad that was useful. So one point to consider as you go through your model regarding disease progression and its slowing: you began with something like a population of advanced CKD patients. Could starting treatment sooner set that timer going earlier and stretch out that 25% reduction? Or does this really only take effect and simply occur down the road, with that 10-year span marking when the clock begins? I believe early on you mentioned essentially no volume effect showing up for roughly 15 years, yet afterward you described how the drug has been in use over the past 7 years. I'm trying to determine when that clock begins for the volume effect.

Jeffrey Giullian

executive
#32

Absolutely. Appreciate it, Kevin; Jeffrey Giullian here once more. A few points. First, with chronic kidney disease broadly, the duration can differ, yet progression from early CKD stage three all the way to end-stage kidney disease frequently takes 15 to 20 years. My understanding is the typical figure sits near 18 years. Even among individuals with diabetes, that span runs 11 to 12 years, or in certain instances, even more.

Javier Rodriguez

executive
#33

Sorry, let me correct. You said three. You meant to say pre.

Joel Ackerman

executive
#34

Right, that's correct. Thanks. When we examine this, having run the models and given it careful consideration, our view is that a significant effect won't show up over the coming 10 years. Taking that a bit further, in reviewing the clinical trials — including even that portion of trials where any kidney effect was shown at all — that effect is markedly smaller among patients who are pre-CKD Stage 3. Kevin, this is Joel. One more thing to add, since we may not be emphasizing enough the possible offset that comes from fewer cardiac deaths, and that ties directly into the question of what effect we're observing and when we observe it. Part of why we believe the current effect is so small, in our view, is that adoption of the drug has remained quite limited. Jeff, tell me if I've got this wrong, but today GLP-1 uptake in CKD sits in the low single digits, isn't that right? At uptake that low, you wouldn't anticipate seeing it. Another key consideration is that for GLP-1s as well as for SGLT2 inhibitors, a decrease in cardiac mortality has been clearly shown. How we see that flowing through our patient population is that far more CKD patients are likely to pass away from cardiac disease than will eventually reach ESRD. So when you're able to lower the count of those dying from cardiac disease, a bigger population remains that might in the end become incident on ESRD, which would counterbalance part of the effect of delaying incidence. And therefore, if today we are observing the negative effect of SGLT2 inhibitors or GLP-1, despite adoption of those drugs being so limited, chances are good that we are simultaneously observing the offsetting benefit regarding cardiac deaths.

Kevin Fischbeck

analyst
#35

All right, that's useful. So perhaps my next question is this: during the quarter, you mentioned that mortality was getting better. Have new starts returned to the level you'd anticipate, or does that metric still need to improve as well?

Joel Ackerman

executive
#36

New starts have come back to the level we'd anticipate. That pressure was felt very strongly by us during the prior year, but at this point we're observing starts on a year-over-year basis returning to what we'd anticipated.

Kevin Fischbeck

analyst
#37

All right, so from your perspective, a 2% increase in volume is the appropriate figure. Over a longer horizon, new starts have returned to their proper level; the only real gap separating the present situation from that 2% is mortality.

Joel Ackerman

executive
#38

I'd say that captures where things stand pretty well.

Javier Rodriguez

executive
#39

Right. If you sharpened things up a bit or refined the picture, our mistreatments are a touch above where they were previously, and that's something we're addressing too. Still, the larger issue is what you're raising.

Kevin Fischbeck

analyst
#40

All right. So given what you're saying — if this drug ends up being adopted and the cardiology upside turns out the way you believe it can — would we observe a higher number of new starts? Is that how it would appear? Would that show up ahead of the progression, or in what way would we actually ever be able to tell that this is how things are unfolding?

Joel Ackerman

executive
#41

Well, I believe the answer is yes, you'd notice it through new starts. What I mean is, you could never single out these particular patients, but they're people who, absent these drugs, would have died at late stage CKD prior to becoming incident to ESRD. Yet that, once again, would be counterbalanced by the postponement of incidents among patients who use these drugs and stay in CKD for a longer period.

Kevin Fischbeck

analyst
#42

All right, that's clear. Then perhaps only one more item. The IKC business is arriving stronger, yet you're still basically holding to that 2026 objective. Is there something odd or from an earlier period in there? Or is it simply too small a shift versus your forecast to really claim the path has sped up?

Joel Ackerman

executive
#43

Yes. So here's the thing — the quarter was genuinely robust, though much of it stemmed from timing. It involved shared savings revenue that had been anticipated for Q4 and showed up during Q3. As we've discussed previously, and which we believe will hold going forward, IKC's quarter-over-quarter swings are pretty substantial, and my view is that the proper lens for IKC is the full year. As things stand, we highlighted roughly a $110 million loss for IKC across the year. That is somewhat improved relative to what we had been describing earlier, yet it is nowhere close to the size of this quarter's beat. And once more, that mostly reflects timing between the current quarter and the following one. So on balance, I'd characterize IKC as on track. Their results are a touch ahead of our expectations, though within the range, and because of that, we still anticipate a stronger figure next year — again during 2025 — and reaching break even by 2026.

Kevin Fischbeck

analyst
#44

All right, great. Thanks.

Javier Rodriguez

executive
#45

Thank you, Kevin.

Lisa Clive

analyst
#46

Hello, and thank you so much. When we discuss late-stage CKD patients, what's the right way to think about how that group gets diagnosed? Clearly, as you're aware, even stage 3 is hugely underdiagnosed, and a lot of effort has gone into changing that; given that today we have various drugs that could genuinely make a difference when they're started early enough, it feels like the correct approach for patients. What's your role in all this, and where do you expect diagnosis rates to head?

Jeffrey Giullian

executive
#47

Thank you, Lisa; it's Jeff speaking once more. A few things come to mind on that. For quite a while there's been an effort to identify CKD patients sooner, and even so, from an epidemiologic view, we aren't observing a significant rise in that. Efforts have been made to spread awareness regarding kidney disease, and similar initiatives. Regarding the treatments on hand, agents such as ACE inhibitors and ARBs, SGLT2 inhibitors, and the GLP-1s, these have existed for quite some time, and what's understood about how they affect the kidneys has been familiar to nephrologists for multiple years; therefore, to us, this isn't really fresh information, even though I realize it's lately been in the news. So looking at it that way, we aren't witnessing much movement. We keep collaborating with physicians further upstream, teaching them about the treatments that exist, and that sort of thing. When we consider in particular what we do within integrated kidney care and making transitions of care better for those patients who ultimately progress to dialysis, that matters to us; together with our physician partners, we routinely manage care for chronic kidney disease patients and work to lower their risk factors.

Lisa Clive

analyst
#48

All right, and I have a follow-up that's connected. If we simply examine how common the disease is as time passes — you know, since we've watched obesity levels move across the past 20 years from roughly 30%-40% of adults — obviously there's been a significant rise in diabetes occurring alongside it, yet at minimum the approximated prevalence — and that's a substantial approximation given how many patients remain undiagnosed — but the approximated prevalence of CKD has actually stayed fairly level throughout that span. Do you have any perspective on what might explain that? I'm simply wondering whether that obesity rate, you know, perhaps even declines, you know, how it would relate to CKD.

Jeffrey Giullian

executive
#49

Yes. The bulk of that approximated prevalence originates from physicians recording CKD as a diagnosis using something known as ICD-10 codes; and therefore when physicians direct their attention toward other matters, cardiovascular risk factors, and cancer-type risk factors and similar items, CKD during its early stages, particularly CKD 1 and 2 and early CKD Stage 3, simply isn't a leading priority, in certain instances. Consequently we aren't observing, at least the documented prevalence of those, climb alongside CKD Stage 3.

Lisa Clive

analyst
#50

All right. Appreciate that.

Pito Chickering

analyst
#51

Hi, everyone; I'll pick things up here with a few brief ones. SG&A had plenty of shifting pieces this quarter, among them, I believe, some funding for the charity groups. Just, you know, wondering whether you could help connect the dots for us on what those shifting pieces were in 3Q, and what our expectations ought to be for G&A in 4Q.

Joel Ackerman

executive
#52

Yeah, on G&A overall, quarter-over-quarter, I don't see much worth flagging. Honestly, nothing stands out. As for Q4, a modest uptick is what I'd anticipate, owing to seasonality, but, nothing significant.

Pito Chickering

analyst
#53

Alright, so revenue per treatment also improved nicely on a sequential basis. Did mix play a role in that, or at this point is it more just a seasonal effect?

Joel Ackerman

executive
#54

Yeah, the largest factor affecting RPT from one quarter to the next was ongoing gains in what we're collecting. From an operations perspective, our team deserves real credit for what they've managed to get done there; we discussed this on the prior call; we picked up a bit additional during this quarter, and I'd say at this point, we've likely captured the great bulk of it, so I don't expect much further improvement on that front over the coming few quarters. We also saw commercial mix rise in the quarter, but on top of that we benefited from certain rate increases that were just negotiated.

Pito Chickering

analyst
#55

At this stage, what kinds of conversations are commercial payers bringing to you?

Joel Ackerman

executive
#56

Pardon me, could you repeat that?

Pito Chickering

analyst
#57

At this point, what sort of rate bumps are the managed care payers providing to you, I suppose?

Joel Ackerman

executive
#58

Well, as we've mentioned previously, our agreements run for multiple years, meaning that during any particular year, only a handful come up for negotiation. What we've observed so far is a great deal of regional accounts, and it's reasonable to state that those rate hikes have mirrored the conditions we find ourselves in — that is, an inflationary setting — so they've come in somewhat above what we saw before the pandemic. And we'll find out what happens in the coming year, since we have a few of the bigger ones scheduled for renewal.

Pito Chickering

analyst
#59

All right. Regarding IKC, my impression is that the situation deteriorated somewhat over the course of the year. If I understood that correctly, what was behind it? And then you mentioned 2024 OI being somewhere around 47%. How much of that comes from IKC getting better as opposed to kidney?

Joel Ackerman

executive
#60

Yes. Pito, I believe you didn't hear that correctly. IKC has actually improved somewhat. Since the guidance we gave previously, we've reduced the loss, so throughout the year we keep seeing progress. As for 2024, providing guidance at this point is premature. Javier mentioned 3%-7% as where we expect the middle of that range to land. Once more, it's too soon to put a number on where that improvement will originate. What I would say is that part of it will certainly come from IKC, though it won't account for the entire amount.

Pito Chickering

analyst
#61

All right, and for my final question, I just want to build on what Kevin asked, particularly regarding Q3. How many new patients were added during Q3? How did that stack up against the pre-COVID baseline? And more specifically, what was mortality for the quarter, and how did it look relative to our pre-COVID level? I'm just trying to understand the relationship between incidents and new patients on one side and extended mortality on the other, to get a sense of treatment growth.

Joel Ackerman

executive
#62

Yes. So volume for the quarter landed exactly where we had anticipated. ... New adds matched what you'd see in a pre-COVID type figure. As for excess mortality, I'll put it at 400. My sense is that excess mortality is a metric we will likely begin retiring. It has gotten so near pre-COVID levels that it now falls inside the margin of error for what we'd regard as our pre-COVID figure, and that figure shifted annually before COVID. So to stay consistent with how we've reported it in the past, the number is 400, but I'd anticipate it will keep falling and eventually, much like contract labor, it mattered for a stretch of time but no longer does; therefore we'll aim to stop using that number moving forward.

Pito Chickering

analyst
#63

All right, that wraps things up on my end, everyone. I really appreciate it.

Joel Ackerman

executive
#64

Appreciate it, Pito.

Lisa Clive

analyst
#65

Hi there. I just wanted to fit in a few questions regarding home dialysis while I have the chance. Could you share any figures about the percentage of your incident private patients who remain employed as opposed to those on COBRA, and what that picture looks like, whether there's any variation among your home dialysis patients, and how we ought to consider that blend moving forward?

Javier Rodriguez

executive
#66

Honestly, I don't have knowledge of the split between COBRA and private, but I do know that figure remains fairly constant when employment is full. Typically it only shifts during recessionary times. So we can examine that, but I don't believe it represents a significant change if that's your aim. And when it comes to home, there is a greater proportion. At present, about 15% and change of our patients are at home, and that figure has held steady; we've kept working hard to bring more patients onto it. However, we haven't observed any insurance-related movement within the cohorts.

Lisa Clive

analyst
#67

All right, I suppose what I was genuinely trying to get at is this: among those private-pay individuals who were able to transition to doing dialysis at home, is it the case that a larger share of them are able to remain in the workforce? My reason for asking is that, as I understood it, when it comes to patients covered under COBRA, many of them are not going to get all the way through those 33 months. Could you weigh in on whether that understanding of mine is accurate, and on whether having more people dialyzing at home might translate into patients holding jobs for a longer stretch?

Javier Rodriguez

executive
#68

Yes, that figure has been something we examined, and analyzing it is genuinely difficult, since it's easy to fall into the correlation-versus-causation pitfall, and what you end up with is a statistic that appears favorable yet in the end fails to produce any improved financial outcomes as the proportion of patients on home dialysis rises. So my characterization of it would be that it's inconclusive. And Lisa, one point worth noting is that over roughly the past 10 years, there's been an assumption that a patient would move to home treatment, gain greater flexibility, and retain the capacity to keep working. What actually happens, though, is that the rate at which people discontinue home dialysis has stayed remarkably elevated. Consequently, approximately 50% of those receiving therapy either prefer to be treated in-center or must be treated in-center owing to a medical condition.

Lisa Clive

analyst
#69

Okay, that's helpful. Thanks.

Javier Rodriguez

executive
#70

Thank you.

Javier Rodriguez

executive
#71

All right, I realize that was quite a packed discussion, and it stood out because it wasn't really tied to the quarter, but rather to something essential for grasping the situation we're in and the situation you're in. So allow me to offer a few final remarks. To start, it was an excellent quarter, and we keep up our record of fulfilling what we've promised. Next, I hope it's now evident that we're quite pleased these medications are available and can better the lives of so many. On the kidney side, though, the picture is more complicated when it comes to grasping what effect it will have across the population. Third, even assuming broad uptake, given what we currently know, we think this category of medicines won't change our intention to achieve 3%-7% OI growth under our long-term plan; and finally, though crucially, we stay extremely dedicated to providing the finest care right now for those we treat, while simultaneously developing the skills and care approaches for a healthier future. It just struck me that this is the final occasion we're set to talk, for the year. So representing our team, I want to wish everyone and their loved ones a joyful and healthy holiday season. Take care.

Operator

operator
#72

Thank you for your participation in today's conference. You may disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.